Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Financial Lp Hrt Acquires 8,266 Shares of Stock

Posted by Doug Wharley on Jul 13th, 2026

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report) major shareholder Financial Lp Hrt acquired 8,266 shares of the stock in a transaction dated Thursday, July 9th. The stock was acquired at an average price of $3.38 per share, for a total transaction of $27,939.08. Following the completion of the acquisition, the insider directly owned 60,540 shares of the company’s stock, valued at $204,625.20. The trade was a 15.81% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

On Friday, July 10th, Financial Lp Hrt bought 731 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.11 per share, with a total value of $2,273.41.
On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.52, for a total transaction of $65,229.12.
On Tuesday, July 7th, Financial Lp Hrt sold 10,580 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.33, for a total transaction of $35,231.40.
On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total transaction of $31,667.22.
On Thursday, July 2nd, Financial Lp Hrt purchased 7,851 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average price of $3.54 per share, for a total transaction of $27,792.54.
On Wednesday, July 1st, Financial Lp Hrt purchased 3,959 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average cost of $3.30 per share, for a total transaction of $13,064.70.
On Tuesday, June 30th, Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.23 per share, with a total value of $21,818.65.
On Monday, June 29th, Financial Lp Hrt acquired 25,836 shares of Shuttle Pharmaceuticals stock. The shares were acquired at an average price of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Trading Up 7.2%

Shares of NASDAQ SHPH traded up $0.21 during mid-day trading on Monday, hitting $3.13. The company had a trading volume of 55,192 shares, compared to its average volume of 547,562. The firm has a 50-day simple moving average of $5.01 and a two-hundred day simple moving average of $10.06. The company has a market capitalization of $1.99 million, a PE ratio of -0.07 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a one year low of $2.71 and a one year high of $55.90.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

Several hedge funds have recently bought and sold shares of SHPH. Ikarian Capital LLC bought a new position in shares of Shuttle Pharmaceuticals during the 4th quarter worth approximately $124,000. Connective Capital Management LLC bought a new stake in Shuttle Pharmaceuticals in the 3rd quarter valued at $357,000. Boothbay Fund Management LLC bought a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at $37,000. Finally, Geode Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals during the 4th quarter valued at $26,000. 4.58% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Weiss Ratings raised Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

View Our Latest Report on SHPH

About Shuttle Pharmaceuticals

(Get Free Report)

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .